SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
STRYKER CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$297.94+3.28 (+1.11%)
Close on Oct 19, 2026
- Market cap
- $115.00B
- P/E (TTM)
- 30.9
- Dividend yield
- –
STRYKER CORP revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $15.20B | $14.88B | $15.65B | $14.05B | $13.57B | $13.48B | $13.52B | $13.39B | $12.93B | $12.57B | $12.16B | $11.74B | 58.8% | +12.0% |
| Orthopaedics: | $10.64B | $10.39B | $9.47B | $10.34B | $10.25B | $9.74B | $9.08B | $8.58B | $8.46B | $8.39B | $8.34B | $8.14B | 41.2% | +3.8% |
| Orthopaedics | $10.64B | $10.39B | $9.47B | $10.34B | $10.25B | $9.74B | $9.08B | – | – | – | – | – | 41.2% | +3.8% |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $4.35B | $4.18B | $4.67B | $3.99B | $3.86B | $3.91B | $4.00B | $3.92B | $3.81B | $3.69B | $3.47B | $3.23B | +12.8% |
| Orthopaedics | $3.36B | $3.25B | $2.82B | $3.20B | $3.15B | $2.88B | $2.59B | – | – | – | – | – | +6.5% |
| Orthopaedics: | – | – | – | – | – | – | – | $2.62B | $2.48B | $2.40B | $2.40B | $2.38B | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other MedSurg And Neurotechnology | – | – | – | – | – | – | – | – | – | – | $343.00M | $336.00M | – | – |
| Neuro Cranial - Interventional Spine | – | – | – | – | $464.00M | $433.00M | $413.00M | – | – | – | – | – | – | – |
| Other Orthopedics - Enabling Technologies | – | – | – | – | $153.00M | $150.00M | $152.00M | – | – | – | – | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $19.45B | $19.04B | $19.01B | $18.44B | $17.98B | $17.47B | $16.94B | $16.43B | $16.00B | $15.66B | $15.26B | $14.76B | 75.3% | +8.2% |
| International | $6.39B | $6.23B | $6.11B | $5.94B | $5.84B | $5.75B | $5.65B | $5.55B | $5.39B | $5.30B | $5.24B | $5.12B | 24.7% | +9.4% |
From the segment and revenue-disaggregation notes of Stryker's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.